In conclusion, we propose that HDAC4 expression, a prognostic and CIN marker, enhances the predictive value of MGMT promoter methylation status for identifying patients who will most benefit from radiochemotherapy. This evidence concerns the gene HDAC4 and cervical squamous intraepithelial neoplasia.